<DOC>
	<DOCNO>NCT00654602</DOCNO>
	<brief_summary>The purpose study assess efficacy safety rosuvastatin reduce low density lipoprotein cholesterol level internationally recognise goal subject dyslipidaemia .</brief_summary>
	<brief_title>48-wk Open Label Phase IIIb Evaluate Efficacy Safety</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Lipid Regulating Agents</mesh_term>
	<criteria>Fasting low density lipoprotein level define protocol . Fasting triglyceride level define protocol . The use lipid lower drug dietary supplement Visit 1 . Active arterial disease eg Unstable angina , recent arterial surgery . Blood lipid level limit define protocol . Uncontrolled hypertension , hypothyroidism , alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>low density lipoprotein</keyword>
	<keyword>dyslipidaemia</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Crestor</keyword>
</DOC>